Comprehensive assessments of the adverse effect profiles of GLP1-RAs, including gastrointestinal disturbances and hypoglycemia, are imperative for informing clinical decision-making and optimizing patient care and PCOS management. This evidence concerns the gene GLP1R and polycystic ovary syndrome.